This post was originally published on this site
(Reuters) – Drugmaker AstraZeneca (NASDAQ:AZN) said on Thursday its cancer drug Imfinzi, when given along with neoadjuvant chemotherapy in a late-stage trial, showed promise in helping patients with an aggressive form of lung cancer before surgery.
The combination showed a statistically significant and meaningful improvement in pathologic complete response compared with neoadjuvant chemotherapy alone in patients with resectable non-small cell lung cancer, the company said.
